Grant Krafft
Co-founder, Acumen Pharmaceuticals; Co-inventor, ACU193-Ph I Alzheimer's drug selectively targets amyloid oligomers, preventing aberrant memory signaling. Adj. Prof. Pharm - Northwestern U.; PhD-Organic chem. U. Illinois; NIH Post-doc fellow U. Wisc.
Grant Krafft
Co-founder, Acumen Pharmaceuticals; Co-inventor, ACU193-Ph I Alzheimer's drug selectively targets amyloid oligomers, preventing aberrant memory signaling. Adj. Prof. Pharm - Northwestern U.; PhD-Organic chem. U. Illinois; NIH Post-doc fellow U. Wisc.
See followers
